Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1980 1
1981 3
1983 2
1984 3
1985 2
1986 4
1987 4
1988 3
1989 7
1990 8
1991 4
1993 1
1994 6
1995 4
1996 2
1997 9
1998 15
1999 13
2000 15
2001 18
2002 30
2003 36
2004 22
2005 27
2006 43
2007 57
2008 61
2009 100
2010 99
2011 115
2012 130
2013 171
2014 206
2015 219
2016 202
2017 245
2018 249
2019 242
2020 285
2021 331
2022 171
Text availability
Article attribute
Article type
Publication date

Search Results

2,810 results
Results by year
Filters applied: . Clear all
Page 1
Influenza and COVID-19: What does co-existence mean?
Chotpitayasunondh T, Fischer TK, Heraud JM, Hurt AC, Monto AS, Osterhaus A, Shu Y, Tam JS. Chotpitayasunondh T, et al. Among authors: shu y. Influenza Other Respir Viruses. 2021 May;15(3):407-412. doi: 10.1111/irv.12824. Epub 2020 Oct 31. Influenza Other Respir Viruses. 2021. PMID: 33128444 Free PMC article. Review.
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Zhou C, et al. Among authors: shu y. Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18. Lancet Respir Med. 2021. PMID: 33347829 Clinical Trial.
Characterizing dedifferentiation of thyroid cancer by integrated analysis.
Luo H, Xia X, Kim GD, Liu Y, Xue Z, Zhang L, Shu Y, Yang T, Chen Y, Zhang S, Chen H, Zhang W, Li R, Tang H, Dong B, Fu X, Cheng W, Zhang W, Yang L, Peng Y, Dai L, Hu H, Jiang Y, Gong C, Hu Y, Zhu J, Li Z, Caulin C, Wei T, Park J, Xu H. Luo H, et al. Among authors: shu y. Sci Adv. 2021 Jul 28;7(31):eabf3657. doi: 10.1126/sciadv.abf3657. Print 2021 Jul. Sci Adv. 2021. PMID: 34321197 Free PMC article.
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH. Wang FH, et al. Among authors: shu yq. J Clin Oncol. 2021 Mar 1;39(7):704-712. doi: 10.1200/JCO.20.02712. Epub 2021 Jan 25. J Clin Oncol. 2021. PMID: 33492986 Free PMC article. Clinical Trial.
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Zhou Q, et al. Among authors: shu yq. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388377 Clinical Trial.
2,810 results